A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults.
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2015
At a glance
- Drugs Dengue subunit vaccine (Primary) ; Aluminium hydroxide; Iscomatrix
- Indications Dengue
- Focus Therapeutic Use
- Sponsors Merck & Co
- 01 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Oct 2013 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Oct 2013 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.